Efficacy In Depression TreatmentGH001 showed impressive reduction in depression scores in the Phase 2b trial for treatment-resistant depression, with a significant number of patients achieving remission.
Financial StabilityGHRS's current cash balance is expected to provide financial stability and support operations into 2026.
Regulatory ProgressGH remains on track to submit a full response to the FDA to address the investigational new drug (IND) hold on GH001, a key regulatory milestone that could enable U.S. entry into a pivotal Phase 3 program.